KINARX, INC

Rockville, MD · Founded 2017 · Biotech · Private

Novel kinase inhibitor molecules for cancer treatment

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · kinarx.com

Sector: Biotech
Headquarters: Rockville, MD
Founded: 2017
Latest Form D: $50K, Feb 2022
Total capital: $3M

Federal grants: $2.8M; 4 awards · 2020–2021; Rank in peer group#354 of 502
Private capital raised: $180K; 2 Form D · last Feb 2022; 57 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Feb 2022Private capital raisedForm D · SEC · 2nd filing$50K
Jun 2021Federal grantHealth and Human S · Phase II · Third line treatment of drug resistant FLT3-positive acute myeloid leukemia with a novel FLT3 kinase inhibitor$1.0M
Jun 2020Federal grantHealth and Human S · Phase I · Aminonaphthyridine compounds as potential therapeutics for lung and thyroid cancers$400K
May 2020Federal grantHealth and Human S · Phase II · Third line treatment of drug resistant FLT3-positive acute myeloid leukemia with a novel FLT3 kinase inhibitor$1M
May 2020Federal grantHealth and Human S · Phase I · Aminonaphthyridine compounds as potential therapeutics for lung and thyroid cancers$400K
Apr 2019Private capital raisedForm D · SEC · 1st filing$130K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Frederick Wayne HoltsbergResearcherExecutive Officer, Director, PromoterLinked by $400K in grants as PI
Javad Aman M.Executive Officer, Director, PromoterNamed in SEC Form D filings
Mohammad Javad AmanExecutive Officer, Director, PromoterNamed in SEC Form D filings
Rena Shira LapidusPromoterNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Integrated Biotherapeutics, Inc.Shares a founder: FREDERICK HOLTSBERG
Kioga Inc.Similar federal contract value in Biotech · null in contracts
ZENA THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
SYNLIFE INCSimilar federal contract value in Biotech · null in contracts
KNOUBIS BIO, INC.Similar federal contract value in Biotech · null in contracts
EPIC NUTRITION FOR Y LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.